BioPharmX Displays Progress in BPX-01 and BPX-04 Clinicals, Analyst Review and Target

BioPharmX Corporation (NYSE American: BPMX) is a Silicon Valley-based specialty pharmaceutical company, which seeks to provide products through proprietary platform technologies for prescription, over-the-counter, and supplement applications in the health and wellness markets, including dermatology and women’s health. 


BioPharmX has successfully completed a phase 2b trial for BPX-01 and is preparing for phase 3 trials in acne.  The company is currently conducting a feasibility study for BPX-04 in rosacea and is preparing for a phase 2 trial. When the company released clinical data for both products recently, the shares gained significantly but have levelled off in recent trading sessions.


On April 26th, the company announced financial results for the quarter and year ended January 31, 2018. The past one year has been filled with numerous milestones and accomplishments for BioPharmX. The company achieved significant clinical milestones, including a successful Phase 2btrial for BPX-01 for acne and the launch of the BPX-04 rosacea program. Furthermore, BPMX was granted three patents from the United States Patent and Trademark Office with numerous patents pending, which demonstrates the robust product pipeline of the company.


Analysts tracking the stock believes that the company is well poised for significant value creation via efficient development and commercialization especially given the fact that BPX-01 and BPX-04 share a novel topical delivery system to carry a minocycline gel to the target area in the skin and will be catering to a large, growing market with significant unmet needs.


Moreover, the company has a presence in a segment which is consolidated right now. In fact, BioPharmX is the first company to develop a topical gel formulation of minocycline that reaches not only the epidermis where rosacea manifests itself but also more in-depth into the pilosebaseous unit, where acne develops. By applying minocycline topically, a patient may reduce the systemic uptake of minocycline and focus the drug’s beneficial effects on the skin where they are needed most.


The market cap of just $46.8 million and share now ruling at $0.24, can move to a level of about $1.50 in next six months or so. Considering all this, the company is in an extremely favorable risk-reward position, and value investors should consider exposure in this sector as the backdrop remains favorable. On the flip side, the company is exposed to the risk associated with any biotech play.


About BPX-01 and BPX-04:

BPX-011 and BPX-041 are hydrophilic (non-oil-based) topical gels with fully solubilized minocycline that have been shown to penetrate the skin to deliver the antibiotic to its target. Following positive results from its previously announced phase 2b dose range study of BPX-01 in acne, BioPharmX continues with phase 3 clinical study plans for BPX-01 for the treatment of inflammatory lesions of acne.


Excerpts from the recent presentation supporting demand drivers for the products:

·       Dermatologists favor medicines that make it easy for patients to follow treatment programs. By reducing the risk of adverse effects and antibiotic resistance, the topical BioPharmX formulations may fulfill needs currently being addressed by a combination of oral antibiotics and topical therapies

·       The fact that this unique hydrophilic delivery system effectively delivers minocycline in a targeted way without the adverse effects associated with either oral antibiotics or many alternative topical products holds exciting promise.

·       Oral minocycline has been widely used since the 1970s, but the pharmaceutical industry has not previously been able to develop a stable, topical formulation of fully solubilized minocycline, which produces less resistance than other tetracycline-class antibiotics commonly used for these diseases.


Pipeline Progress:

Fourth Quarter 2018 Results:

Expenses: For the fourth quarter ended January 31, 2018, total operating expenses were $3.6 million, compared with total operating expenses of $4.3 million in the prior fiscal year’s fourth quarter.

Net loss for the fourth quarter of 2018 was $3.8 million, or $0.03 per share, compared with a net loss of $5.2 million, or $0.09 per share, during the prior fiscal year’s fourth quarter. 

Full Year Financial Results

Expenses: Total operating expenses for the fiscal year were $16.7 million, compared with $18.0 million in the prior fiscal year. The decrease resulted primarily from lower expenditures for the company’s clinical trial activities related to BPX-01.

Net loss for the fiscal year was $16.6 million, or $0.19 per share, compared with a net loss of $18.5 million, or $0.52 per share, during the prior fiscal year. 

Liquidity and financial flexibility: Cash and cash equivalents as of January 31, 2018, were $7.6 million.  Additionally, BioPharmX reported that after the end of the year and through the date of this press release, the company received $7.0 million in cash through warrant exercises subsequent to January 31, 2018.


Key risk factors and potential stock drivers:

·       Successful completion of the upcoming milestones would lead future direction for the company. Any adversities related to these forthcoming milestones might adversely impact the overall investor sentiments.

·       BPMX is still an early stage entity and has not yet generated revenue and will likely operate at a loss as it grows its market position and seeks ways to monetize it. The company’ prospects are significantly dependent on BPX-01 and BPX-04, which might have limited sales potential initially.

·       BPMX has a history of operating losses. Therefore, any time or cost overrun in its ongoing R&D activities and its impact on business & financial profile will remain a key business sensitivity factor.


Stock Chart:


  • On Wednesday, June 6th, 2018, BPMX was at $0.24, on volume of 1.1 million shares exchanging hands. Market capitalization is $46.846 million. The current RSI is at 55.01
  • In the past 52 weeks, shares of BPMX have traded as low as $0.10 and as high as $0.548
  • At $0.24, shares of BPMX are trading above its 50-day moving average (MA) at $0.22 and above its 200-day moving average (MA) at $0.21
  • The present support and resistance levels for the stock are at $0.23 & $0.26 respectively. 






Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.

Traders News Source has not been compensated for this report by anyone and the opinions if any are that of the author Vikas Agrawal, CFA. Author’s Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I, wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in the article.

This web site, published by TNS LLC, and is an investment newsletter that is built on the premise of assisting individual investors in learning about investing. Our goal as publishers of financial information is to provide research and analysis of investments to our subscribers. TNS LLC does not give buy or sell recommendations. We do purchase distribution rights from analyst, financial writers and bloggers for a fee that may be licensed to issue price targets and recommendations. Furthermore, we encourage you to speak to a licensed professional prior to making an investment in any type of publicly traded security.

We do sell advertising to other companies including brokerage firms, web sites, publicly traded issuers, investor relations firms, and investment publications, among others. TNS LLC makes no warranty as to the policies of these organizations, and in no way endorses their offers, services, or the content of their advertisements.

When an advertiser is a publicly traded company or a third party acting on behalf of a public company, we fully disclose all compensation in the email advertisement. Such disclosure is included in a disclosure statement in each of the advertisements sent via email.

17B Disclosure

Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.

PLEASE NOTE WELL: TNS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.

Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operator’s owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D.

TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.

The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur.

Understand there is no guarantee past performance will be indicative of future results. In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.